MAB348-AF647

Anti-APP A4, a.a. 66-81 of APP {NT} Antibody, clone 22C11, Alexa Fluor^™ 647 Conjugate

clone 22C11, from mouse, ALEXA FLUOR^™ 647

• Synonim(y): Amyloid beta A4 protein, ABPP, Alzheimer disease amyloid protein, Amyloid precursor protein, APP, APPI, Cerebral vascular amyloid peptide, CVAP, PN-II, PreA4, Protease nexin-II, PN-II, N-APP, Soluble APP-alpha, S-APP-alpha, Soluble APP-beta, S-APP-beta,
• Kod UNSPSC: 12352203
• eCl@ss: 32160702
• NACRES: NA.41

Właściwości

• pochodzenie biologiczne: mouse
• Poziom jakości: 100
• białko sprzężone: ALEXA FLUOR^™ 647
• forma przeciwciała: purified antibody
• rodzaj przeciwciała: primary antibodies
• klon: 22C11, monoclonal
• reaktywność gatunkowa: canine, porcine, rat, fish, human, monkey, mouse
• metody: immunocytochemistry: suitable
• izotyp: IgG1
• numer dostępu NCBI: NM_000484.2; NM_201413.1; NM_201414
• numer dostępu UniProt: P05067
• Warunki transportu: wet ice
• docelowa modyfikacja potranslacyjna: unmodified
• informacje o genach: human ... APP(351)

Opis

Opis ogólny

Amyloid beta A4 protein (UniProt P05067; also known as ABPP, Alzheimer disease amyloid protein, Amyloid precursor protein, APP, APPI, Cerebral vascular amyloid peptide, CVAP, PN-II, PreA4, Protease nexin-II) is encoded by the APP (also known as A4, AD1) gene (Gene ID 351) in human. Amyloid precursor protein (APP) is initially produced with a signal peptide sequence (a.a. 1-17), the removal of which yields the mature protein with a large extracellular portion (a.a. 18-699), followed by a transmembrane segment (a.a. 700-723) and a cytoplasmic (a.a. 724-770) tail. APP can be further processed by the α-, β-, and γ-secretases in two alternative processing pathways. In the non-amyloidogenic pathway, APP is first cleaved by the plasma membrane-localized α-secretase to generate an N-terminal extracellular sAPPα fragment (a.a. 18-687) and a membrane-bound C-terminal fragment C83 (CTFα), which can be further cleaved by γ-secretase to produce a non-toxic small peptide p3 and a cytoplasmic APP intracellular domain (AICD). In the amyloidogenic pathway, APP undergoes β-cleavage in BACE-1 (β-site APP-cleaving enzyme)-enriched endosomes to generate an N-terminal extracellular sAPPβ fragment (a.a. 18-671) and a membrane-bound C-terminal fragment C99 (CTFβ). Subsequent cleavage of C99 by γ-secretase releases the amyloid β peptide (Aβ) and AICD. Aβ accumulation in the cortical and hippocampal regions of the brain is a major pathological feature of Alzheimer′s disease (AD).

Zastosowanie

Anti-APP A4, a.a. 66-81 of APP {NT} Antibody, clone 22C11, Alexa Fluor^™ 647 Conjugate is an antibody against APP A4 for use in Immunocytochemistry.

Jakość

Evaluated by Immunocytochemistry in SH-SY5Y cells.

Immunocytochemistry Analysis: A 1:100 dilution of this antibody detected APP A4 in SH-SY5Y cells.

Opis wartości docelowych

~110/120/130 kDa observed.

Inne uwagi

Concentration: Please refer to lot specific datasheet.

Informacje prawne

ALEXA FLUOR is a trademark of Life Technologies

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 12 - Non Combustible Liquids
• Klasa zagrożenia wodnego (WGK): WGK 2
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable